Holen Sie sich die Stockscreener-App
4.9782
6.06%
-0.3518
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
DEADLINE ALERT for HDB, SMPL, and AARD: The Law Offices of - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. LawsuitAARD - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
Aardvark Therapeutics Lawsuit: Investors Can Lead Securities Fraud Case - WBOC TV
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) - GlobeNewswire
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline - PR Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-09-06 | AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:AARD | Press Release - Stockhouse
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - TMX Newsfile
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) S - The National Law Review
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - Morningstar
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark Therapeutics, Inc. Class Action Lawsuit Alert: - GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark - GlobeNewswire
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark - GlobeNewswire
Important Notice to Long-Term Shareholders Aardvark - GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark - GlobeNewswire
AARD STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (AARD) Investors - The National Law Review
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - Morningstar
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (AARD) to Filing of Securities Class Action - TMX Newsfile
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
AARD DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aardvark Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - The Chronicle-Journal
AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aardvark Therapeutics, Inc. Investors - GlobeNewswire
Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit - Business Wire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aardvark - GlobeNewswire
Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD - newsfilecorp.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Shareholders who lost money in shares of acquired Aardvark - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
2026-08-21 | Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action | NDAQ:AARD | Press Release - Stockhouse
Aardvark Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsAARD - WBOC TV
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Sahm
Aardvark Therapeutics (AARD) gives director 10-year options at $6.54 - Stock Titan
Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops - TipRanks
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation - Morningstar
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026AARD - Business Wire
Aardvark Therapeutics Faces Securities Class Action Lawsuit - Intellectia AI
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
Aardvark (AARD) Quarterly Figures: EPS Falls Short of Its Estimate in the Current Update; Share Move: The Stock Records a 9.85% Increase in the Latest SessionEarnings Power Value - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
Lawsuit ALERT: Investors who lost money with shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) - openPR.com
AARD Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):